Functional Deletion/Insertion Promoter Variants in SCARB1 Associated With Increased Susceptibility to Lipid Profile Abnormalities and Coronary Heart Disease

Senlin Hu1,2, Dong Hu1,2, Haoran Wei1,2, Shi-yang Li1,2, Dong Wang1,2, Chen-ze Li1,2, Jianguang Jiang1,2, Daowen Wang1,2, Guanglin Cui1,2* and Daowu Wang3*

1 Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Hubei Province Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Huazhong University of Science and Technology, Wuhan, China, 3 State Key Laboratory of Reproductive Medicine, The Center for Clinical Reproductive Medicine and Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Background: Genetic variants in Scavenger receptor Class B Type 1 (SCARB1) influencing high-density lipoprotein cholesterol (HDL-C) and coronary heart disease (CHD) risk were identified by recent genome-wide association studies. Further study of potential functional variants in SCARB1 may provide new ideas of the complicated relationship between HDL-C and CHD.

Methods: 2000 bp in SCARB1 promoter region was re-sequenced in 168 participants with extremely high plasma HDL-C and 400 control subjects. Putative risk alleles were identified using bioinformatics analysis and reporter-gene assays. Two indel variants, rs144334493 and rs557348251, respectively, were genotyped in 5,002 CHD patients and 5,175 control subjects. The underlying mechanisms were investigated.

Results: Through resequencing, 27 genetic variants were identified. Results of genotyping in 5,002 CHD patients and 5,175 control subjects revealed that rs144334493 and rs557348251 were significantly associated with increased risk of CHD [odds ratio (OR): 1.28, 95% confidence interval (CI): 1.09 to 1.52, p = 0.003; OR: 2.65, 95% CI: 1.66–4.24, p = 4.4 × 10^{-5}). Subsequent mechanism experiments demonstrated that rs144334493 deletion allele attenuated forkhead box A1 (FOXA1) binding to the promoter region of SCARB1, while FOXA1 overexpression reversely increased SR-BI expression.

Conclusion: Genetic variants in SCARB1 promoter region significantly associated with the plasma lipid levels by affecting SR-BI expression and contribute to the susceptibility of CHD.

Keywords: SCARB, lipids, genetics, variant, coronary heart disease
INTRODUCTION

Dyslipidemia is one of the major risk factors of coronary heart disease (CHD) (1). An inverse relationship between high-density lipoprotein (HDL) cholesterol (HDL-C) and the risk of CHD was identified by population-based studies (1, 2). However, clinical trials with drugs, niacin, and cholesteryl ester transfer protein (CETP) inhibitors, which could raise HDL-C level, have produced disappointing results (3). The causal role of HDL-C in cardio-protection has been questioned by genetic and randomized studies (4, 5), which suggests that HDL components rather than cholesterol may account for the anti-atherothrombotic effects of this lipoprotein. Indeed, HDL subspecies related to HDL function might provide new information to the prediction of cardiovascular disease risk (6). Although previous literatures found that individuals may not be protected against CHD by higher HDL-C level, we proposed that further human genetic analysis might provide new insight into the complicated relationship between HDL and CHD.

Scavenger receptor class B member 1 (SR-BI) is the major receptor for HDL (7). Transgenic mice overexpressing SR-BI was protected against atherosclerosis, while SR-BI deficiency could increase atherosclerosis, ignoring the increased levels of HDL-C, likely resulted from decreased hepatic delivery as well as clearance of cholesterol (8–13). To date, increasing evidences have demonstrated that variants of SCARB1 were associated with plasma lipid levels (14), carotid intimal medial thickness (15), insulin sensitivity (16), and risk of CHD (17). In 2011, Vergeer et al. identified a new missense variant in the coding-region of SCARB1, which resulted in increased HDL cholesterol level, reduced intensity of efflux of cholesterol from macrophages, impaired platelets function, and diminished adrenal function (18). Recently, a rare homozygous variant in a subject with high HDL-C was identified by resequencing of SCARB1, which could raise HDL-C level and increase risk of CHD (19). However, most of the current studies mainly focused on the coding variant, only a few publications studied the non-coding region. Through genotyping of 690 participants, Hsu et al. identified an 11-bp deletion variant in the promoter region of SCARB1 which explained a significant proportion of difference in individual HDL-C levels (20). Even so, the genome-wide association studies (GWAS) identified loci only explained a small proportion of HDL-C variation, suggesting that additional pathways and targets may exist. Furthermore, new molecular interactions can be defined through bioinformatic approaches of large-scale RNA sequencing data and genotypic data and further identify biologically meaningful gene networks which could control the metabolism of HDL and occurrence of related disease end points.

Because the plasma HDL-C concentration is inversely associated with increased risk of CHD, and SR-BI is the key molecule of HDL-C metabolism, further study of the sequencing variant of this gene may provide new insight into the complex relationship between HDL-C and CHD. Based on our resequencing results, we identified two variants, rs144334493, which located in the FOXA1 binding site, and an 11-bp deletion variant rs557348251 in the promoter region of SCARB1. We hypothesized that these two variants could modify SR-BI expression and contribute to the genetic susceptibility of CHD.

MATERIALS AND METHODS

Study Design and Eligibility

The procedure of data collection, inclusion criteria, sample recruitment, and definition of risk factors were provided in our previous report (21, 22). Clinical characteristics of the study sample are listed in Table 1. In general, resequencing was conducted in 168 Han Chinese subjects with an HDL cholesterol level over the 95th percentile (>2.0 mmol/L) and a control group of 400 subjects. These participants were recruited in Wuhan Tongji Hospital from individuals who underwent routine health examinations. The 5,175 healthy control participants were community-based Chinese Han individuals recruited in 2012 from the general population, with ages ranging from 27 to 86 years. The CHD cohort, including 5,002 patients, was enrolled simultaneously between May 2004 and October 2015 from hospitalized patients in the Tongji Hospital. Details of the selection criteria, biochemical and clinical characteristics of the participants were described in our previous report (21, 22). All participants provided written informed consent. Experiments were performed in adherence to the Declaration of Helsinki. This study was conducted with the permission of institutional ethics committees of the local hospital.

Genetic Variation Screening

Sequence data at the SCARB1 promoter region was generated by DNA sequencing. Polymerase-chain-reaction (PCR) covering the promoter region (SCARB1 consensus sequence NC_000012.11 GRCh37.p13) was performed followed by Fluorescent dye-terminator cycle. Analysis of the products were carried out using an Applied Biosystems 3130xl capillary sequencer (Applied Biosystems, Foster City, CA). Putative polymorphisms were identified applying the Chromas program (Technelysium Pty. Ltd., Helensvale, Queensland, Australia) and confirmed by two independent observers. The identified variants were verified by repeat sequencing. Primers used for resequencing are given in Supplementary Table 1.

In silico Analyses

HaploRegv4.1 (http://archive.broadinstitute.org/mammals/haploreg/haploreg.php) was used to identify the linkage disequilibrium of the SNPs (23). GWAS loci of SCARB1 were derived from GWAS Catalog (www.ebi.ac.uk/gwas/home) (24). Possible functional variants were looked up in the RegulomeDB (http://www.regulomedb.org/index) database (25). Transcription factors with potential allele-specific binding efficacy were predicted with JASPAR2016 (http://jaspar2016.genereg.net/) (26).

Abbreviations: CHD, coronary heart disease; FOXA1, forkhead box A1; GWAS, genome-wide association study; HDL-C, high-density lipoprotein cholesterol; LD, linkage disequilibrium; LDL-C, low-density lipoprotein cholesterol; SCARB1, Scavenger receptor Class B Type 1; SNP, single nucleotide polymorphism.
### TABLE 1 | Baseline characteristics of the study samples.

| Cohort | High HDL-C sequencing cohort cases (n = 168) | Control sequencing cohort cases (n = 400) | The general population | The CHD population |
|--------|---------------------------------------------|------------------------------------------|------------------------|---------------------|
|        | Controls (n = 5,175)                         | Cases (n = 5,002)                         |                        |                     |
| Age, yrs | 60.6 ± 10.6      | 59.7 ± 10.1 | 56.59 ± 10.01 | 60.36 ± 10.34 |
| Male, % | 60.8            | 34.9  | 48.04 | 72.98 |
| BMI, kg/m² | 21.2 ± 2.1 | 22.7 ± 2.8 | 23.72 ± 3.38 | 23.72 ± 3.38 |
| TC, mmol/L | 4.58 ± 0.40 | 4.57 ± 0.91 | 4.56 ± 0.96 | 4.14 ± 1.04 |
| HDL-C, mmol/L | 2.19 ± 0.19 | 1.52 ± 0.31 | 1.33 ± 0.33 | 1.01 ± 0.26 |
| LDL-C, mmol/L | 1.86 ± 0.47 | 2.57 ± 0.76 | 2.58 ± 0.76 | 2.45 ± 0.85 |
| TG, mmol/L | 0.77 ± 0.24 | 1.18 ± 0.50 | 1.32 ± 0.77 | 1.53 ± 1.01 |
| Blood pressure, mm Hg |                          |                        |                          |                     |
| Systolic | 137.9 ± 26.9 | 133.3 ± 23.3 | 135.90 ± 23.37 | 134.24 ± 20.67 |
| Diastolic | 83.0 ± 16.0 | 81.6 ± 11.8 | 80.28 ± 12.20 | 80.17 ± 13.02 |
| Hypertension | 91 (54.2) | 177 (44.3) | 1,577 (30.47) | 3,006 (60.10) |
| Type 2 diabetes | 0            | 1 (0.3) | 319 (6.16) | 1,087 (21.73) |
| Current/ex-smoker | 0            | 0      | 1,284 (24.81) | 2,391 (47.80) |
| Previous myocardial infarction | 0            | 0      | 0            | 1,832 (36.63) |
| Heart failure | 0            | 0      | 0            | 40 (0.80) |
| History of cerebrovascular disease | 0            | 0      | 343 (6.63) | 600 (12.00) |
| Coronary angiography |                          |                        |                          |                     |
| 0-vessel disease | —        | —      | —            | 44 (0.88) |
| 1-vessel disease | —        | —      | —            | 1,493 (29.85) |
| 2-vessel disease | —        | —      | —            | 1,608 (32.15) |
| 3-vessel disease | —        | —      | —            | 1,837 (36.73) |
| Left main trunk disease | —        | —      | —            | 407 (8.14) |
| Right coronary artery stenosis | —        | —      | —            | 3,535 (70.67) |

Values are mean ± SD or n (%). BMI, body mass index; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.

### Functional Analysis

Bioinformatic analysis shows that among the 12 common SNP with MAF > 0.01, 4 were annotated by RegulomeDB with a score less or equal to 3. Since rs181338950 was proved to be no function in a previous study (>0.01), 4 were annotated by RegulomeDB with 0.8<0.01. Functional Analysis shows that among the 12 common SNP with MAF > 0.01, 4 were annotated by RegulomeDB with a score less or equal to 3. Since rs181338950 was proved to be no function in a previous study (>0.01), 4 were annotated by RegulomeDB with 0.8<0.01.

### Luciferase Assay

HepG2 cells (1 × 10⁶ cells per well) were used and co-transfected with 0.8 μg of PGL3-WT or PGL3-MU plasmid and 50 ng of Renilla luciferase, combined with lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instruction. After 48 h of transection, cells were washed and lysed using Passive Lysis Buffer (SIRIUS, Pforzheim, Germany). The luciferase activities were detected with a luminometer (SIRIUS, Pforzheim, Germany) and calculated relative to Renilla luciferase activity and compared with negative control in each group. Among the 4 SNPs, the relation of rs144334493 and 4 predicted transcription factors were further investigated. HepG2 cells (1 × 10⁶ cells per well) were used and co-transfected with 0.8 μg of PGL3-insert or PGL3-deletion reporter vector of rs144334493 and 50 ng of Renilla luciferase, with 250 ng of PGL3-insert or PGL3-deletion reporter vector and resultant plasmids (PGL3-WT and PGL3-MU of each polymorphism respectively) were transfected into HepG2 cells, to determine effects of the variants by detecting fluorescence intensity according to the manufacturer’s instruction. Primers used for vector construction are given in Supplementary Table 2.

### Genotyping and Capillary Electrophoresis

SNP genotyping was performed in this study using the TaqMan SNP Genotyping Assay (Applied Biosystems). Genomic DNA extracted from peripheral leukocytes was used as previously reported (22). Probe and primer sequences applied for the TaqMan 5′-nuclease assay were produced by the ABI Primer Expression 3.0 software and then synthesized by Shanghai GeneCore BioTechnologies Co., Ltd, China. ABI 7900 HT Fast Real-Time PCR System (Applied Biosystems) was used for the analysis of the samples following the undermentioned conditions: 10 min at 95°C (enzyme activation), and 40 cycles at 95°C for 15 s followed by 60°C for 1 min (annealing/extension).
An endpoint read was performed to determine the allelic discrimination results after amplification. Details were provide in our previous report regarding the performance for amplification reactions as well as the quality of genotyping (22). The 11 bp deletion variant rs557348251 was genotyped using Capillary electrophoresis method. In brief, PCR products were generated using FAM labeled forward primer. After purification, products were separated by Capillary electrophoresis with an Applied Biosystems 3130xl capillary sequencer (Applied Biosystems, Foster City, CA). Applied Biosystems GeneMapper 4.0 was used to identify putative polymorphisms. The identified variants were then confirmed by repeat sequencing. Probes and primers used are given in Supplementary Table 4.

**Western Blotting for SR-BI**

Cell transfection experiments were performed using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the instruction manual. In brief, HepG2 cells grown in six-well plates were transfected with 2,000 ng pcDNA3.1(+)(-)-FOXA1, pcDNA3.1(+)(-)-CLOCK, pcDNA3.1(+)(-)-MYC, pcDNA3.1(+)(-)-MLXIPL, respectively, pcDNA3.1(+) empty vector was used as negative control. After 48 h of transfection, the harvested cells were homogenized with lysis solution (50 mM Tris-Cl, pH 8.0; 1% Nonidet P-40; 150 mM NaCl; 0.1% SDS; 0.02% sodium azide; 0.5% sodium deoxycholate; and 1 µg/ml aprotinin) containing protease inhibitors (2 µg/ml leupeptin, 2 µg/ml aprotinin, 100 µg/ml phenylmethylsulfonyl fluoride). After centrifuging at 12,000 g for 20 min at 4°C, supernatant was collected. Protein concentration was measured with the BCA protein assay reagent kit (Boster, China). Lysates were resolved using 10% SDS-polyacrylamide gel electrophoresis. Products were transferred to polyvinylidene difluoride (PVDF) membranes. Following blocking with 5% non-fat milk, protein blots were probed with SR-BI (Lot No: BST17584233, Boster, China) or FLAG (#14793, Cell Signaling) antibody (1:1,000 diluted) and incubated with a peroxidase-conjugated secondary antibody. GAPDH was used as internal reference. Enhanced chemiluminescence reagents (Pierce Chemical, Rockford, IL) were used to visualize the protein bands, which were then quantified by densitometry.

**Chromatin Immunoprecipitation Assay**

ChIP assays were performed using the ChiP Assay Kit (P2078, ChiP Assay Kit, Beyotime, China) according to the instruction manual. In brief, HepG2 or HEK293 cells (1 × 10⁶) were treated with 1% formaldehyde for 10 min at 37°C. Then, cells were collected and lysed in SDS lysis buffer. A sonic Dismembrator 550 (Fisher Scientific, Pittsburgh, PA) was used for eight 30-s cycles of sonication of the cell lysates. The input was phenol/chloroform-extracted and then ethanol-precipitated followed by ChiP-qPCR with control primers and primers that amplified 205 bases surrounding the rs144334493 variant in both rabbit IgG treated (control group) or anti-Flag antibody treated (anti-Flag group) group. ChiP-qPCR was done using ABI 7900HT Fast Real-Time PCR System (Applied Biosystems) with following conditions: 10 min at 95°C (enzyme activation), and 40 cycles at 95°C for 15 s followed by 60°C for 1 min (annealing-extension). Relative expression was calculated according to the ΔΔCq method using the Ct values provided by the manufacturer and compared between control and anti-flag group. Primers used for CHIP assay are given in Supplementary Table 5.

**Electrophoretic Mobility-Shift Assay**

Commercial EMSA kit was used for the Electrophoretic mobility-shift assay (GS009, Chemiluminescent EMSA Kit, Beyotime, China) in this study. In brief, nuclear protein isolated from HepG2 cells applying Nuclear-Cytoplasmic Extraction Kit (Applygen Technologies Inc, Beijing, China) was quantified with the BCA Protein Assay Kit (Boster, China). The rs144334493 insertion allele and deletion allele labeled oligonucleotides were commercially synthesized (Sangon Biotech, Shanghai, China). Gel shift assays were conducted with the LightShift Chemiluminescent EMSA kit (GS009, Beyotime) following the manufacturer’s instructions. For competition experiments, unlabeled rs144334493 insertion or deletion oligonucleotides in 100 fold molar excess were added followed by the addition of the biotinylated probes as well as anti-Flag antibodies (#14793, Cell Signaling) used in supershift assays. Three independent experiments were performed for the analysis. Sequence of probes and primers are given in Supplementary Table 6.

**Real-Time RT-PCR Analysis**

To determine the association between genotype and in vivo SR-BI expression, we included 64 control subjects in Wuhan Tongji Hospital who underwent routine health examinations. Characteristics of the study samples are given in Supplementary Table 7. Peripheral blood leukocytes were used for the extraction of total RNA using TRIzol reagent (Invitrogen). One microgram of total RNA was used for reverse transcription with PrimeScript RT reagent Kit with gDNA Eraser (Perfect Real Time) (Takara, Code No. RR047A). Real time PCR assays with SYBR Green (Takara, Code No. RR820L) were performed for measurement of SR-BI expression. ACTB was used as internal reference. Reaction was performed in triplicate with the primers listed in Supplementary Table 8. SR-BI expression was determined using the ΔΔCq method and compared between study subjects with different rs144334493 genotypes.

**Statistical Analysis**

SPSS 13.0 (SPSS Inc, Chicago, IL) for Windows (Microsoft Corp, Redmond, Wash) was used for the statistical analyses. Linkage disequilibrium (LD) was calculated with Haploview version 4.2. Chi-square tests were performed to assess deviations of genotype frequency from the Hardy-Weinberg assumption. Multivariate linear regression analysis was performed to test associations between the SNPs and lipid traits using the additive
### TABLE 2 | Characteristics of SCARB1 promoter variants identified by resequencing in Control/High HDL-C cases.

| Gene position | dbSNP ID | Gene region | Maj> Min | Control MAF | High HDL-C cases MAF | P-value |
|---------------|----------|-------------|----------|-------------|----------------------|---------|
| chr12:125350530 | rs79134272 | Promoter | G/A | 0.315 | 0.349 | 0.119 |
| chr12:125350495 | c.-2229C>T | Promoter | C/T | 0.001 | 0.000 | 0.836 |
| chr12:125350454 | rs144334493 | Promoter | GCT/- | 0.110 | 0.103 | 0.621 |
| chr12:125350368 | c.-2102T>G | Promoter | T/G | 0.000 | 0.007 | 0.160 |
| chr12:125350360 | c.-204C>A | Promoter | C/A | 0.001 | 0.000 | 0.657 |
| chr12:125350320 | rs4569100 | Promoter | C/T | 0.255 | 0.253 | 0.858 |
| chr12:125349968 | rs12580521 | Promoter | G/C | 0.253 | 0.253 | 0.993 |
| chr12:125349897 | c.-1631G>A | Promoter | G/A | 0.001 | 0.000 | 0.658 |
| chr12:125349949 | rs12322330 | Promoter | C/T | 0.315 | 0.349 | 0.113 |
| chr12:125349638 | rs58157328 | Promoter | C/T | 0.083 | 0.135 | 0.208 |
| chr12:125349519 | rs36226544 | Promoter | C/T | 0.255 | 0.254 | 0.976 |
| chr12:125349449 | c.-1228G>A | Promoter | G/A | 0.000 | 0.007 | 0.156 |
| chr12:125349480 | rs36226283 | Promoter | C/T | 0.257 | 0.254 | 0.914 |
| chr12:125349374 | rs112822039 | Promoter | A/G | 0.003 | 0.000 | 0.531 |
| chr12:125349360 | c.-1094C>T | Promoter | C/T | 0.003 | 0.000 | 0.531 |
| chr12:125349194 | rs4765182 | Promoter | G/C | 0.329 | 0.350 | 0.334 |
| chr12:125349192 | rs36226280 | Promoter | G/C | 0.001 | 0.000 | 0.658 |
| chr12:125349188 | c.-922G>T | Promoter | G/T | 0.001 | 0.000 | 0.658 |
| chr12:125349060 | rs373875675 | Promoter | G/A | 0.001 | 0.000 | 0.656 |
| chr12:125349014 | c.-748T>G | Promoter | T/G | 0.001 | 0.000 | 0.656 |
| chr12:125348988 | rs59358115 | Promoter | C/T | 0.122 | 0.110 | 0.647 |
| chr12:125348890 | c.-624G>C | Promoter | G/C | 0.001 | 0.000 | 0.656 |
| chr12:125348777 | c.-611G>A | Promoter | G/A | 0.003 | 0.000 | 0.528 |
| chr12:125348828 | c.-562G>A | Promoter | G/A | 0.001 | 0.000 | 0.656 |
| chr12:125348652 | c.-316C>A | Promoter | G/A | 0.001 | 0.000 | 0.657 |
| chr12:125348548 | rs181338950 | Promoter | C/T | 0.103 | 0.096 | 0.624 |
| chr12:125348536 | rs557348251 | Promoter | TCCCCGCCCCG/- | 0.025 | 0.048 | 0.169 |

All variants had at least a 90% genotype call rate and were in Hardy-Weinberg equilibrium (P > 0.05).
*Base pair position is based on NCBI GRCh37.
†Polymorphisms are numbered relative to transcription start site.
‡With major allele given first followed by minor allele; MAF, Minor allele frequency.
P-value: significance of minor allele frequency differences determined by Chi-square tests, cases vs. controls.

### TABLE 3 | SNPs in strong linkage disequilibrium (r² > 0.8) in the promoter region of SCARB1 and RegulomeDB scores for predicted function.

| SNP | Chromosome | Position (GRCh37) | D' | r² | RegulomeDB score |
|-----|------------|-------------------|----|----|-----------------|
| rs79134272 | 12 | 125350530 | 1 | 1 | 3a |
| rs12322330 | 12 | 125349849 | 0.975 | 0.951 | 5 |
| rs4765182 | 12 | 125349194 | 0.974 | 0.888 | 2b |
| rs144334493 | 12 | 125350454 | 1 | 1 | 2b |
| rs59358115 | 12 | 125349888 | 0.972 | 0.852 | 4 |
| rs181338950 | 12 | 125348548 | 0.97 | 0.866 | 2a |
| rs4569100 | 12 | 125350320 | 1 | 1 | 5 |
| rs12580521 | 12 | 125349968 | 1 | 0.979 | – |
| rs36226544 | 12 | 125349519 | 1 | 0.993 | – |
| rs36226283 | 12 | 125349480 | 0.993 | 0.986 | – |
| rs58157328 | 12 | 125349638 | – | – | 6 |
| rs557348251 | 12 | 125348536 | – | – | – |

RegulomeDB scores for predicted function (1 = likely to be functional; and 6 = not likely to be functional). Linkage disequilibrium values were obtained from the resequencing data. SNP indicates single nucleotide polymorphism.
genetic model adjusted by conventional vascular risk factors. Quantitative variables were analyzed using the Student t-test. The CHD risk was compared between disease and control groups using unconditional logistic regression analysis based on different genetic model after adjustment of conventional risk factors.

All biostatistics calculations were carried out using Prism5 (GraphPad). Comparisons among multiple conditions were conducted with ANOVA followed by post hoc t-tests. Comparisons between two groups were calculated using unpaired t-tests. Data are expressed as mean ± SEM of n experiments. The probability values were 2-sided, and p < 0.05 was considered significant.

RESULTS

DNA Resequencing and Effects of Polymorphisms on Vitro Activity of the SCARB1

In total, 27 genetic variants were identified in our resequencing cohort consisted of 168 participants with extremely high plasma HDL-C and 400 control subjects, of which 12 were common variants with Minor allele frequency >0.01, as shown in Table 2. However, none of the distribution of the identified variants were statistically significant between the two groups.

To identify potential functional variants, we defined the haploblock structure of the 12 common SNPs within the SCARB1 promoter region using genotypes of the 400 control subjects (Supplementary Figure 1). Further bioinformatics analysis revealed that 4 of these common variants were annotated by RegulomeDB database with a score less or equal to 3 (Table 3), indicating that these variants are likely to be functional. Since rs181338950 was confirmed as a non-functional variant by a previous study through reporter gene assay (20), DNA sequences of 250 bp flanking the other three SNPs, respectively, were constructed into PGL3-Basic reporter vector. As shown in Figure 1, only rs144334493 variant had significant effect on the luciferase activity (Figures 1A–C). In HepG2 cells, reporter gene expression for rs144334493 mutant deletion allele was significantly decreased compared with rs144334493 wide-type insertion allele (50 ± 8.33%, P < 0.001) (Figures 1C,D). Furthermore, previous study identified a functional 11-base pair indel polymorphism rs557348251 which was also confirmed in our resequencing analysis without functional annotation (20). The rs557348251 polymorphism showed no linkage disequilibrium with the other 11 common SNPs and thus was also included in our following analysis.

Association of Rs144334493 and Rs557348251 Variant With Lipid Levels and Risk of CHD

To investigate the association between rs144334493, rs557348251 and plasma lipid levels and risk of CHD, we conducted genotyping using TaqMan probes and capillary electrophoresis in 5,175 control subjects and 5,022 CHD patients (Figures 2A–C). The relationship between rs144334493, rs557348251, and plasma lipid levels was analyzed in the 5,175 control subjects (Table 1). The rs144334493 polymorphism associated with decreased plasma levels of APOA1 (β = −0.188 mmol/L, p = 0.024) (Supplementary Table 9). Rs557348251 deletion allele was significantly associated with increased plasma TC and LDL-C levels (β = 0.270 mmol/L, p = 0.040; β = 0.293 mmol/L, p = 0.019, respectively) (Figure 2D), subjects carrying the rs557348251 deletion allele tend to have decreased plasma levels of APOA1 (β = −0.086 g/L, p = 0.080) (Figure 2D, Supplementary Table 10).

Results of the CHD patients showed that rs144334493 deletion allele was significantly associated with increased risk of CHD independent of conventional risk factors (additive model, OR: 1.28, 95% CI: 1.09–1.52, p = 0.003; dominant model, OR: 1.28, 95% CI: 1.06–1.54, p = 0.011; recessive model, OR: 2.01, 95%CI: 1.12–3.62, p = 0.020). Similar results were confirmed for rs557348251 in the case-control study (additive model, OR: 2.65, 95% CI: 1.66–4.24, p = 4.4×10−5; dominant model, OR:
FIGURE 2 | Genotyping and sequencing of rs557348251 and the association with plasma lipid levels. (A) Cross-species sequence alignment of SCARB1 promoter region showing conservation of base pair positions in which rs557348251 variant was identified (included in blue Rectangle). (B) Capillary electrophoresis graphic of the three genotypes of rs557348251. Upper, homozygote major; middle, heterozygote; lower, homozygote minor. (C) Sequencing chromatogram for the three genotypes of rs557348251 (included in red Rectangle). (D) Association of rs557348251 genotype with lipid levels in the general population. Lipid levels are expressed as fold change relative to the non-deletion carrier group. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.

3.00, 95% CI: 1.82–4.95, \( p = 1.8 \times 10^{-5} \); recessive model, OR: 1.63, 95%CI = 0.27–9.88, \( p = 0.598 \) (Table 4).

Combined analysis of the rs144334493 deletion allele and rs557348251 deletion allele with CHD was conducted. Results showed that carriers of both rs144334493 and rs557348251 deletion allele have significantly increased risk of CHD compared with the none deletion allele carriers, after adjusting for the conventional risk factors (OR: 3.88, 95%CI = 2.04–7.39, \( p = 3.8 \times 10^{-5} \)) (Table 5).

Population Angiographic Characteristics of the CHD Cases

The CHD cases were documented angiographically as having >50% diameter stenosis in at least 1 coronary artery. The angiographic characteristics between different genotypes of rs144334493 and rs557348251 were analyzed (Supplementary Tables 11, 12). Both rs144334493 and rs557348251 deletion allele significantly associated with increased modified Gensini score (Figure 3A). Rs144334493 deletion allele carrier showed significantly increased proportion of incidence of right coronary artery stenosis and multi-vessel disease (\( p = 0.005 \), \( p = 0.009 \), respectively; Figure 3B). The rs557348251 homozygotes also showed increased proportion of multi-vessel disease (\( p = 0.043 \)) (Figure 3C). Details of the association of the variants with angiographic characteristics were shown in Supplementary Tables 11, 12. Further in vivo SR-BI expression study revealed that rs144334493 variant was associated with decreased expression of SR-BI (Figure 3D).

Variant Rs144334493 Located in the FOXA1 Binding Site

Subsequent bioinformatics analysis showed that rs144334493 occurred in the conservative binding site of transcription factor FOXA1, CLOCK, MYC, and MLXIPL. To test the prediction model that these transcription factors could functionally interact with rs144334493 sequence, luciferase reporter vectors containing the rs144334493 insert or deletion allele were co-transfected with either pcDNA3.1(+)-FOXA1, pcDNA3.1(+)-CLOCK pcDNA3.1(+)-MYC, pcDNA3.1(+)-MLXIPL constructs or pcDNA3.1(+)- empty vector in HepG2 cells. The PGL3 vector containing the rs144334493 GCT insertion allele showed a significant increase in luciferase activity in the presence of FOXA1, while overexpression of MYC, MLXIPL, and CLOCK didn’t influence the reporter activity (Supplementary Figure 2). It’s worth noting that, in the presence of FOXA1, rs144334493 deletion allele construct still showed...
Hu et al. SCARB1, Common Variant, and CHD Risk

In this study, we discovered are that the deletion allele of the variants rs144334493 and rs557348251, in SCARB1 promoter region, are significantly associated with increased risk of CHD (Figure 5). The rs557348251 variant dramatically increases risk of CHD in great amplitude and changes lipid levels. The deletion allele of rs144334493 attenuated FOXA1-induced expression of SR-BI. These associations are independent of conventional risk factors.

HDL-C level is inversely associated with CHD risk. SCARB1 gene encoded the major receptor of HDL (7) which mediate the selective uptake of HDL-C. The normal function of this receptor is to transport cholesterol from the plasma into liver and steroidogenic organs like adrenal gland. Scarb1 knockout in mice resulted in higher HDL-C and increased risk of atherosclerosis (11, 12, 27–30). Reversely, overexpression of Scarb1 is associated with lower plasma levels of HDL-C and attenuated progression of atherosclerosis (8–10, 31). Therefore, targeting SR-BI is an attractive way to modulate plasma lipid level and hence reduce residual cardiovascular risk. With the development of the “Next-generation” sequencing technology, loss-of-function mutations of the SCARB1 gene were identified to be associated with increased HDL-C levels and increased risk of ischemic vascular disease (18). This led to the hypothesis that adverse effect on CHD could be observed in carriers of SCARB1 loss-of-function

TABLE 4 | Association between rs144334493 variant with CHD.

| SNP rs ID       | Function | Population | MAF | $P_{\text{allele}}$ | MM | Mm | mm | Model | Crude ORs (95%CI) | Adjusted ORs (95%CI) | $P_{\text{value}}$ | Adjusted ORs (95%CI) | $P_{\text{value}}$ |
|-----------------|----------|------------|-----|---------------------|----|----|----|-------|------------------|-------------------|----------------|-------------------|----------------|
| rs144334493     | Promoter | Control    | 0.127 | 0.003 | 3,948 | 1,140 | 87 |       | 1                | 1                 | 1                | 1                |
| (GCT $>$ T)     |          | CHD        | 0.131 |         | 3,784 | 1,124 | 94 | Additive | 1.05 (0.97–1.13) | 0.003 | 1.28 (1.09–1.52) | 1                |
| rs557348251     | Promoter | Control    | 0.024 | $1.18^*10^{−15}$ | 4,933 | 234 | 8 |       | 1                | 1                 | 2.66 (2.25–3.16) | 4.4$^*10^{−5}$ | 2.65 (1.66–4.24) |
| (TCCCCGCCCCG $>$ T) |          | CHD        | 0.052 |         | 4,513 | 454 | 35 | Additive | 2.86 (2.38–3.42) | 1.8$^*10^{−5}$ | 3.00 (1.82–4.95) | 1                |
|                 |          | CHD        |        |         | 4.88 | 2.25–10.55 | 0.598 |       | 1.63 (0.27–9.88) |                   |                   |                   |

CHD, Coronary Heart Disease; M, major allele; m, minor allele; MAF, minor allele frequency. $P_{\text{allele}}$ value and Crude odds ratio (OR) (95% confidence interval) were determined by a 95% two-sided $\chi^2$ test, CHD vs. controls. Adjusted ORs (95% CI) and adjusted $P_{\text{value}}$ were obtained with multivariate unconditional logistic regression analysis by adjusting for sex, age, smoking, hypertension, hyperlipidemia, diabetes, and body mass index.

TABLE 5 | Association between numbers of variations with CHD.

| Population | Num. None | One | Two | Num. None | One | Two | Crude ORs (95%CI) | Adjusted ORs (95%CI) | $P_{\text{value}}$ |
|------------|-----------|-----|-----|-----------|-----|-----|------------------|-------------------|----------------|
| Control    | 3,734     | 1,413 | 28 |           |     |     |                  |                   |                  |
| CHD        | 3,398     | 1,501 | 103|           |     |     |                  |                   |                  |

CHD, Coronary Heart Disease; Num., numbers of the two deletion allele; None, none deletion allele carrier; One, carrier of rs144334493 or rs557348251 deletion allele; Two, carrier of both rs144334493 or rs557348251 deletion allele; Crude odds ratio (OR) (95% confidence interval (CI)) were determined by a 95% two-sided $\chi^2$ test, CHD vs. controls. Adjusted ORs (95% CI) and adjusted $P_{\text{value}}$ were obtained with multivariate unconditional logistic regression analysis by adjusting for sex, age, smoking, hypertension, hyperlipidemia, diabetes, and body mass index.

Reduced luciferase activity than that of the rs144334493 insertion allele construct (18 ± 12%, $P = 0.03$) (Supplementary Figure 2).

In order to further confirm the effect of FOXA1 on endogenous SR-BI expression, we sequenced six of the human hepatoma cell lines (including 97L, 7702, 7721, Hep1, Hep3B, and HepG2), all of which were identified to be rs144334493 insertion allele homozygotes (Supplementary Figure 3), and next we used HepG2 cell line to do experiments. Results showed that overexpression of FOXA1 significantly increased the expression of SR-BI, which was consistent with results of the reporter gene assay (Figure 4A). In contrast, the transcription factor CLOCK slightly decreased the expression of SR-BI, while both MYC and MLXIPL didn’t influence the expression of SR-BI (Supplementary Figure 4). Chromatin immunoprecipitation experiment demonstrated that rs144334493 was located in the FOXA1 binding site in both HepG2 and 293T cells (Figures 4B,C). Further in vitro electrophoretic mobility shift assay revealed that FOXA1 may preferentially bind to the rs144334493 insertion allele rather than the deletion allele of rs144334493, although no supershift band was presented (Supplementary Figure 5). These results indicated that rs144334493 may affect SR-BI expression by allele-specific FOXA1 binding.

These results suggested that decreased SR-BI expression caused by genetic variations may be a possible pathogenic mechanism of CHD.
mutations. However, most of studies were focused on the coding region. In our study, \textit{SCARB1} promoter region were re-sequenced in 400 control subjects and 168 participants with extremely high plasma HDL-C levels.

Up to now, GWASs were extensively used for the identification of common variants, termed SNPs, which were associated with different human traits. Nevertheless, protein-coding genes constitute only a limited proportion of the human genome. Study of the common variants in the non-coding regulatory region can provide new underlying mechanisms for the understanding of human traits and disease. Genetic studies have demonstrated that variant of \textit{SCARB1} were associated with gene expression and plasma lipid levels (32), body mass index in white population (33), carotid intimal medial thickness (15), post-prandial lipid levels (16, 34), insulin sensitivity (16), risk of coronary heart disease (17), risk of peripheral arterial disease (35), age-related macular degeneration (36), and response to fenofibrate intervention (37). But study

---

**FIGURE 3** | Association of rs144334493 and rs557348251 genotype with CHD gensen score, RCA stenosis, and multivessel disease of CHD. (A) The rs144334493 and rs557348251 variants associated with Gensini score adjusted by age, sex, hypertension, diabetes, and body mass index. (B) Proportion of CHD patients with RCA stenosis in different rs144334493 genotype. (C) Multivessel disease of CHD associated with variant rs557348251. (D) Association between variant rs144334493 and the \textit{SCARB1} gene expression. Data are means ± SE from 64 independent samples, as described in the Methods, analyzed in three replicates normalized with ACTB mRNA. CHD, coronary heart disease; MAF, minor allele frequency; RCA, right coronary artery.
on the association between polymorphisms and risk of CHD in the promoter region of \textit{SCARB1} is lacking (20). The SNP rs144334493 which is located in the promoter region of \textit{SCARB1} was located in the DNaseI hypersensitivity site as annotated by ENCODE (http://genome.ucsc.edu/). No previously association of this variant with lipid and CHD risk was reported. Meanwhile, the rs557348251 variant was located in about 20 bp upstream of \textit{SCARB1} transcription start site with a very high GC content. We found that rs144334493 deletion allele significantly influence relative luciferase expression. Thus, this lead to the hypothesis that rs144334493 may be a functional variant.

SR-BI is a key receptor of HDL-C metabolism and plays an important role in reverse cholesterol transport. Elevated HDL-C levels are inversely associated with cardiovascular disease. However, genetic variants which result in loss of function and attenuated expression and function of SR-BI are associated with increased risk of coronary heart disease (19). Recently, Lu et al. reported East Asian-specific coding variants influences lipid levels and contributes to coronary artery disease (38). However, none of these two indel variants in the promoter region of \textit{SCARB1} was covered. In 2003, Hsu et al. reported an 11 bp deletion variant in the promoter region of \textit{SCARB1} which can affect transcription factor SP1 binding and significantly influence HDL-C level while having no effect on other lipid components like LDL-C, TC, TG [(20), Figure 5]. Considering its limited sample size and sequencing coverage, whether there exit functional variant in the promoter region of \textit{SCARB1} which may have both influence on lipid level and CHD risk is worth of research.

In this study, we identified two common functional variant rs144334493 and rs557348251 in the promoter region of \textit{SCARB1} which were significantly related to the risk of CHD. The 11 bp indel variant rs557348251 was also associated with increased LDL-C. According to our resequencing results, rs59358115 and rs181338950, were in strong linkage disequilibrium (LD) ($r^2 > 0.8$) with rs144334493, respectively. Furthermore, based on the 1,000 Genome data (http://grch37.ensembl.org/Homo_sapiens/), rs59358115 and rs181338950 were in modest LD ($r^2 = 0.013, D' = 1$) with the known GWAS loci rs11057864 (Supplementary Table 13). Indicating that rs144334493 may be the causal functional variant. Functional investigation demonstrated that the rs144334493 variant was located in the conserve binding site of transcription factor FOXA1, which
FIGURE 5 | Diagram of the promoter sequence of the SCARB1 gene. Rs144334493 and rs557348251 were located in the promoter region of SCARB1. Rs144334493 deletion allele was associated with loss of transcription factor FOXA1 binding site, while rs557348251 deletion allele was reported to influence SP1 binding. Both deletion alleles were associated with increased risk of CHD.

can promote the expression of SR-BI, as confirmed by western blot assay. FOXA1 encodes a member of the forkhead class of DNA-binding proteins, and can activate liver-specific transcripts such as albumin (39). It also participates in the development of breast cancer (40). However, whether FOXA1 participates in the regulation of lipid metabolism, especially on SR-BI function have not been investigated. In this study, we firstly discovered that FOXA1 can increase the expression of SR-BI through conserved binding site flanking rs144334493. The association of the rs557348251 variant with CHD risk was more robustly than that of rs144334493, accompany with only a modest increase of HDL-C [Beta (SE) in SD = +0.57 (0.071)] (19). This result requires further elucidation in the future.

In conclusion, our findings provide evidence that the rs144334493 deletion allele in the promoter region of SCARB1 might increase the risk of CHD, probably by attenuating FOXA1 binding, which would lead to the under-expression of SR-BI, and further cause the reduction of reverse cholesterol efflux and increased risk of CHD. Meanwhile, another 11 bp deletion promoter variant rs557348251 also significantly associated with increased plasma levels of TC and LDL-C accompanied by strongly increased susceptibility to CHD. These results might help to improve the understanding of HDL-C metabolism, the CHD genetic risk evaluation and further prevention or therapy strategies of CHD by targeting SR-BI.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: Genbank with accessions BankIt2528919 Seq1 OL878355 BankIt2528919 Seq2 OL878356 BankIt2528919 Seq3 OL878357 BankIt2528919 Seq4 OL878358 BankIt2528919 Seq5 OL878359 BankIt2528919 Seq6 OL878360 BankIt2528919 Seq7 OL878361 BankIt2528919 Seq8 OL878362 BankIt2528919 Seq9 OL878363 BankIt2528919 Seq10 OL878364.

ETHICS STATEMENT

This study was approved by the institutional review board of Tongji hospital. Written informed consent was obtained from all participants. Experiments were conducted according to the Declaration of Helsinki.

AUTHOR CONTRIBUTIONS

SH participated in the research design, carried out the epidemiological investigation, undertook sequencing and genotyping, performed statistical analyses, and drafted the manuscript. DH collected samples, constructed vectors and executed the cell experiment. HW, S-YL, and C-ZL participated in the epidemiological investigation and collected samples for this study. DWeW participated in the research design, carried out the epidemiological investigation. GC conceived and no replication study was conducted. Further larger patient populations are needed to confirm our findings. Thirdly, in vitro EMSA assay indicated allele-specific binding of FOXA1 at the rs144334493 site, however, no significant supershift band was detected. The regulatory pattern of FOXA1 on SR-BI expression needs to be clarified in further studies. Another limitation of our study is that the relationship between plasma lipid levels, SCARB1 gene variation and CHD development has not been well-established. Zanoni et al. demonstrated that loss-of-function variant of SCARB1 was associated with elevated level of subfractions of HDL and risk of CHD, which was associated with only a modest increase of HDL-C [Beta (SE) in SD = +0.57 (0.071)] (19). This result requires further elucidation in the future.
the study, participated in the research design, collected samples, and edited the final manuscript. JJ carried out the epidemiological investigation and collected samples. DWuW provided intellectual support for the revised manuscript. All authors have read and approved the final manuscript.

FUNDING
This work was supported by the National Natural Science Foundation of China (Nos. 81770351 and 81630010) and the National Precision Medicine Program (No. SQ2017YFSF090157).

REFERENCES
1. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. (2009) 302:1993–2000. doi:10.1001/jama.2009.1619
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med. (1977) 62:707–14. doi:10.1016/0002-9343(77)90874-9
3. Rader DJ, Tall AR. The not-so-simple HDL story: is it time to revise the HDL hypothesis? Nat Med. (2012) 18:1344–6. doi:10.1038/nm.2937
4. Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Jensson BÖ, et al. Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease. Eur Heart J. (2018) 39:2172–8. doi:10.1093/eurheartj/ehy169
5. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. (2008) 299:2524–32. doi:10.1001/jama.299.21.2524
6. Jensen MK, Aroner SA, Mukamal KJ, Furtado JD, Post WS, Tsai MY, et al. Subspecies defined by presence of apolipoprotein c-iii and incident coronary heart disease in four cohorts. Circulation. (2018) 137:1364–73. doi:10.1161/CIRCULATIONAHA.117.031276
7. Steinberg D, A. docking receptor for HDL esters. Science. (1996) 271:460–1. doi:10.1126/science.271.5248.460
8. Wang N, Ariai T, Ji Y, Rinninger F, Tall AR. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J Biol Chem. (1998) 273:32920–6. doi:10.1074/jbc.273.49.32920
9. Ariai T, Wang N, Bezouevski M, Welch C, Tall AR. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem. (1999) 274:23666–71. doi:10.1074/jbc.274.4.2366
10. Kozarsky KF, Donahue MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol. (2000) 20:721–7. doi:10.1161/01.ATV.20.3.721
11. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M, et al. Targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA. (1997) 94:12610–5. doi:10.1073/pnas.94.23.12610
12. Trigatti B, Rayburn H, Viitala M, Braun A, Miettinen H, Penman M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA. (1999) 96:3922–7. doi:10.1073/pnas.96.13.3922
13. Hoekstra M, van Berkel T-J, van Eck M. Scavenger receptor BI: A multipurpose player in cholesterol and steroid metabolism. World J Gastroenterol. (2010) 16:5916–24. doi:10.3748/wjg.v16.i47.5916
14. Helgadottir A, Sulem P, Thorgerisson G, Gretarsdottir S, Thorleifsson G, Jansson BO, et al. Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease. Eur Heart J. (2018) 39:2172–8. doi:10.1093/eurheartj/ehy169
15. Fox CS, Cupples LA, Chazaro I, Polak JF, Wolf PA, D’Agostino RB, et al. Genomewide linkage analysis for internal carotid artery intimal medial thickness: evidence for linkage to chromosome 12. Am J Hum Genet. (2004) 74:253–61. doi:10.1086/381559
16. Pérez-Martínez P, Pérez-Jiménez F, Bellido C, Ordovás JM, Moreno JA, Marín C, et al. polymorphism exon 1 variant at the locus of the scavenger receptor class B type I (SCARB1) gene is associated with differences in insulin sensitivity in healthy people during the consumption of an olive oil-rich diet. J Clin Endocrinol Metab. (2005) 90:2297–300. doi:10.1210/jc.2004-1489
17. Rodríguez-Esparragón F, Rodríguez-Pérez JC, Hernández-Trujillo Y, Macias-Reyes A, Medina A, Caballero A, et al. Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: Genotype-phenotype correlations. Arterioscler Thromb Vasc Biol. (2005) 25:854–60. doi:10.1161/01.ATV.0000157581.88838.03
18. Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, et al. Genetic Variant of the Scavenger Receptor BI in Humans. N Engl J Med. (2011) 364:136–45. doi:10.1056/NEJMoa1007687
19. Zanon P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. (2016) 351:1166–71. doi:10.1126/science.aad3517
20. Hsu LA, Ko YL, Wu S, Teng MS, Peng TY, Chen CF, et al. Association between a novel 11-base pair deletion mutation in the promoter region of the scavenger receptor class B type I gene and plasma HDL cholesterol levels in Taiwanese Chinese. Arterioscler Thromb Vasc Biol. (2003) 23:1869–74. doi:10.1161/01.ATV.0000082525.84114.A9
21. Ding H, Wu B, Wang H, Lu Z, Yan J, Wang X, et al. A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease. Circ Res. (2010) 106:1145–52. doi:10.1161/CIRCRESAHA.109.215816
22. Cui G, Li Z, Li R, Huang J, Wang H, Zhang L, et al. functional variant in APOA5/A4/C3/A1 gene cluster contributes to elevated triglycerides and severity of CAD by interfering with microRNA 3201 binding efficiency. J Am Coll Cardiol. (2014) 64:267–77. doi:10.1016/j.jacc.2013.04.050
23. Ward LD, Kellis M. HaplOpReg v4: Systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. (2016) 44:D877–81. doi:10.1093/nar/gkv1340
24. MacArthur J, Bowler E, Cerezo M, Gil L, Hall P, Hastings E, et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res. (2017) 45:D986–901. doi:10.1093/nar/gkw1133
25. Boyle AP, Hon GL, Harirah M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. (2012) 22:1970–7. doi:10.1101/gr.137323.112
26. Mathelier A, Fornes O, Arenillas DJ, Chen CY, Denay G, Lee J, et al. Nucleic Acids Res. (2016) 44:D110–6. doi:10.1093/nar/gkv1176
27. Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IS, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism

ACKNOWLEDGMENTS
We would like to thank the cardiologists in Division of cardiology for their efforts in collecting samples for this study. We also want to acknowledge all the participants in this study.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.800873/full#supplementary-material

January 2022 | Volume 8 | Article 800873 | Frontiers in Cardiovascular Medicine | www.frontiersin.org
in cells of the arterial wall and in the liver. *J Biol Chem.* (2003) 278:23699–705. doi: 10.1074/jbc.M211233200

28. Trigatti BL. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. *Arterioscler Thromb Vasc Biol.* (2003) 23:1732–8. doi: 10.1161/01.ATV.0000091363.28501.84

29. Huszar D, Varban ML, Rinninger F, Feeley R, Arai T, Fairchild-Huntress V, et al. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. *Arterioscler Thromb Vasc Biol.* (2000) 20:1068–73. doi: 10.1161/01.ATV.20.4.1068

30. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. *Circ Res.* (2002) 90:270–6. doi: 10.1161/01.RES.0000091363.28501.84

31. Constantineau J, Greason E, West M, Flibin M, Kief JS, Carletti MZ, et al. A synonymous variant in scavenger receptor, class B, type I gene is associated with lower SR-BI protein expression and function. *Atherosclerosis.* (2010) 210:177–82. doi: 10.1016/j.atherosclerosis.2009.11.029

32. Acton S, Osgood D, Donoghue M, Corella D, Pocovi M, Cenarro A, et al. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. *Arterioscler Thromb Vasc Biol.* (1999) 19:1734–43. doi: 10.1161/01.ATV.19.7.1734

33. Tanaka T, Delgado-Lista J, Lopez-Miranda J, Perez-Jimenez F, Marin C, Perez-Martinez P, et al. Scavenger receptor class B type I (SCARB1) c.1119CT polymorphism affects postprandial triglyceride metabolism in men. *J Nutr.* (2007) 137:578–82. doi: 10.1093/jn/137.3.578

34. Zerbib J, Seddon JM, Richard F, Reynolds R, Leveziel N, Benlian P, et al. rs5888 variant of SCARB1 gene is a possible susceptibility factor for age-related macular degeneration. *PLoS ONE.* (2009) 4:e7341. doi: 10.1371/journal.pone.0007341

35. Lui Y, Or dovas JM, Gao G, Province M, Straka RJ, Tsai MY, et al. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. *J Hum Genet.* (2008) 53:709–17. doi: 10.1007/s10038-008-0302-2

36. Lu X, Peloso GM, Liu DJ, Wu Y, Zhang H, Zhou W, et al. Exome chip meta-analysis identifies novel loci and East Asian-specific coding variants that contribute to lipid levels and coronary artery disease. *Nat Genet.* (2017) 49:1722–30. doi: 10.1038/ng.3978

37. Lau HH, Ng NH, Loo LSW, Jasmen JB, Teo AKK. The molecular functions of hepatocyte nuclear factors - in and beyond the liver. *J Hepatol.* (2018) 68:1033–48. doi: 10.1016/j.jhep.2017.11.026

38. Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, et al. Recurrent and functional regulatory mutations in breast cancer. *Nature.* (2017) 547:55–60. doi: 10.1038/nature22992

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Hu, Hu, Wei, Li, Wang, Li, Jiang, Wang, Cui and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.